脂质体包封增强利帕舒地尔对增殖性玻璃体视网膜疾病的疗效:晚期眼科治疗的意义
本研究通过脂质体包封利帕舒地尔(Lipo-Ripa),在晚期AMD模型和兔PVR模型中评估其抑制视网膜下纤维化和PVR进展的效果,并进行药代动力学研究。结果显示Lipo-Ripa较单用利帕舒地尔显著减少视网膜下纤维化并更有效抑制兔PVR进展,且玻璃体和视网膜滞留增加、RPE屏障通透性降低、细胞摄取增加,眼内药物浓度持续升高。作者认为脂质体包封可增强利帕舒地尔的生物利用度和有效性,为增殖性玻璃体视网膜病变提供有前景的创新治疗途径。
要点
- Lipo-Ripa在晚期AMD模型中显著减少视网膜下纤维化。
- Lipo-Ripa在兔PVR模型中较单用利帕舒地尔更有效抑制PVR进展。
- Lipo-Ripa改善玻璃体和视网膜滞留、降低RPE屏障通透性并增加细胞摄取。
核心结论
- 作者认为脂质体包封利帕舒地尔可增强药物生物利用度和有效性,为增殖性玻璃体视网膜病变提供有前景的创新治疗途径。
研究设计与样本
- 研究进行利帕舒地尔脂质体包封后,开展全面的体内和体外分析及药代动力学研究。
- 体内实验包括晚期AMD模型和兔PVR模型。
主要发现
- Lipo-Ripa在晚期AMD模型中显著减少视网膜下纤维化。
- Lipo-Ripa在兔PVR模型中较单用利帕舒地尔更有效抑制PVR进展。
- 药代动力学研究显示Lipo-Ripa在玻璃体和视网膜中滞留能力改善,同时RPE屏障通透性降低、细胞摄取增加。
- 上述特性导致眼内组织药物浓度随时间持续升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Proliferative vitreoretinal diseases, such as proliferative vitreoretinopathy (PVR) and neovascular age-related macular degeneration (nAMD), pose substantial challenges in their advanced stages owing to the development of retinal fibrous membranes. Current therapeutic modalities, including surgical interventions for PVR and antivascular endothelial growth factor therapy for nAMD, cannot effectively manage intraocular fibrosis associated with epithelial-to-mesenchymal transition (EMT) in retinal pigment epithelium (RPE) cells. Through drug screening, we identified ripasudil, a Rho-kinase inhibitor, as a remarkable suppressor of RPE-EMT. However, the short vitreal half-lives of small-molecule drugs, coupled with the limited stability of ripasudil in the ocular environment, impede its application in vitreoretinal diseases. Considering the advances in nanotechnology-assisted improvement in drug stability and cellular uptake as well as controlled release, we aimed to enhance the efficacy of ripasudil through liposome encapsulation. METHODS: After ripasudil encapsulation, we performed comprehensive in vivo and in vitro analyses and pharmacokinetic studies. RESULTS: Liposome-encapsulated ripasudil (Lipo-Ripa) demonstrated a substantial reduction in subretinal fibrosis in an advanced AMD model and more effective inhibition of PVR progression in rabbits than that induced by ripasudil alone. Pharmacokinetic studies revealed that Lipo-Ripa exhibited improved retention capacity in the vitreous and retina, alongside reduced permeability through the RPE barrier and increased cellular uptake. These characteristics resulted in a sustained elevation of drug concentration within the ocular tissues over time. CONCLUSIONS: Our findings suggest that liposomal encapsulation of ripasudil supports enhanced bioavailability and effectiveness of the drug, presenting a promising innovative therapeutic approach for the treatment of proliferative vitreoretinopathy.
引用
- Ji R, Ishikawa K, Tan W, et al. Liposome Encapsulation Enhances Ripasudil Therapeutic Efficacy Against Proliferative Vitreoretinal Diseases: Implications in Advanced Ocular Treatment. Invest Ophthalmol Vis Sci. 2025. PMID: 40525920. doi:10.1167/iovs.66.6.56
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。